Footnote

This summary is built on the strongest available evidence: cardiorespiratory fitness (CRF), of which VO₂ max is the gold-standard index, is one of the most powerful modifiable predictors of all-cause and cause-specific mortality, and structured aerobic exercise, particularly high-intensity interval training (HIIT), is the only intervention with high-certainty human evidence for raising it.[1][2][3] Pharmacological “longevity” agents (metformin, NAD⁺ precursors, senolytics, mitochondrial small molecules) do not have robust human evidence for improving VO₂ max and are explicitly flagged below as experimental or research-only.[4][5]

1. Scope

– Covered: Assessment and optimisation of VO₂ max/CRF in community-dwelling adults attending a UK private longevity clinic, as an adjunct to conventional primary and secondary care. Focus is on exercise prescription (the evidence-based core), plus a critical appraisal of adjunctive/experimental interventions marketed for “mitochondrial” or “longevity” benefit.

– Not covered: Elite sports performance optimisation, disease-specific cardiac rehabilitation prescribing (defer to cardiology), management of established cardiomyopathy/valvular disease, and paediatrics.

– Positioning: All recommendations are adjunctive. Patients with known or suspected cardiovascular, respiratory or metabolic disease should remain under, or be referred to, appropriate NHS specialist care.

2. Background and pathophysiology

– VO₂ max is the maximal rate of oxygen uptake during incremental exercise, determined by central (cardiac output, haemoglobin, pulmonary gas exchange) and peripheral (capillary density, skeletal-muscle mitochondrial content and oxidative capacity) factors. It is the integrative “whole-organism” measure of aerobic reserve.

– Ageing relevance: VO₂ max declines ~10% per decade from mid-life, accelerating after age 70, driven by falling maximal heart rate, reduced stroke volume, sarcopenia and mitochondrial decline. Low CRF tracks with the ageing hallmarks of mitochondrial dysfunction and chronic inflammation.[6][7]

– Mechanisms targeted by training: aerobic exercise increases mitochondrial biogenesis and mitophagy, capillarity, stroke volume/plasma volume and endothelial function (flow-mediated dilation), and reduces arterial stiffness.[8][9]

– Preclinical only (clearly marked): rapamycin, metformin and NAD⁺ precursors improve mitochondrial function and extend healthspan/lifespan in rodents and lower organisms; dietary restriction remains the gold-standard preclinical intervention. These effects are not established as translating into VO₂ max gains in humans.[10][7][4]

3. Evidence base and grading

Outcome	Evidence statement	GRADE certainty	Strength of recommendation
CRF/VO₂ max → all-cause mortality	Overview of meta-analyses (199 cohorts, >20.9M observations): high vs low CRF HR 0.47; each 1-MET ↑ associated with 11–17% lower mortality; confirmed in 37-cohort meta-analysis (n≈2.26M), RR 0.89 per MET [1], [2]	Moderate (observational; consistent, large, dose-response; downgraded for indirectness/confounding)	Strong rationale to treat VO₂ max as a clinical vital sign [11]
Exercise training → ↑ VO₂ max	Meta-analyses/umbrella reviews of RCTs: HIIT raises peak VO₂ ~3.9 mL/kg/min vs control (>1 MET), and ~1.3 mL/kg/min more than MICT [3], [12], [13]	High	Strong — offer aerobic training
HIIT → cardiometabolic surrogates (BP, lipids, insulin, hs-CRP, body composition)	Meta-analysis of 17 parameters across RCTs shows significant improvement [3]; Cochrane review supportive [8]	Moderate–High	Strong (surrogates)
Exercise training → mortality/morbidity reduction (hard endpoints)	Extrapolated from CRF–mortality gradient + prevention data (JACC seminar) [14]; no RCT powered on longevity endpoints for VO₂-targeted training	Low for causal mortality benefit of a specific VO₂ target	Conditional — mechanistically strong but not proven by RCT on hard endpoints
Metformin / NAD⁺ precursors / senolytics → ↑ VO₂ max or longevity in humans	No adequately powered RCT demonstrates VO₂ max improvement or mortality benefit in non-diabetic adults; human data limited/mixed; TAME not yet reported [4], [5]	Very low	Only in research / Recommend against routine use for this indication

The strength of the CRF–mortality relationship is illustrated below, where low fitness exceeds conventional risk factors as a mortality predictor.

Figure 2 Relative Mortality Risk Associated With Select Clinical Characteristics

4. Patient selection and indications

– Who benefits (offer):

– Middle-aged adults (≈40–65) with high cardiometabolic risk (central obesity, prediabetes/T2DM, hypertension, dyslipidaemia) — largest absolute gain from a low baseline.[3][8]

– Sedentary adults of any age with measured low CRF for age/sex percentile.[11]

– Older adults (≥65) seeking to preserve independence — with a modified, function-first approach.[16][17]

– Clinical scenario nuance: athletic individuals seeking further gains derive small marginal mortality benefit (dose-response flattens at high CRF); frame as performance rather than longevity.

– Exclusion / specialist input first: unstable angina, decompensated heart failure, severe/symptomatic aortic stenosis, uncontrolled arrhythmia, uncontrolled hypertension (>180/110), recent MI/ACS, acute myocarditis, uncontrolled diabetes, or acute illness. These require medical clearance before vigorous testing or training.

– Regulatory/ethical status: Exercise prescription is on-label/standard care. Metformin, rapamycin, NAD⁺ precursors and senolytics for VO₂ max/longevity are off-label and experimental — appropriate only within clinical trial frameworks or, at most, as informed-consent adjuncts with explicit documentation that human efficacy is unproven.[4][5]

5. Assessment and baseline work-up

– History & examination: cardiovascular symptoms (chest pain, syncope, exertional dyspnoea, palpitations), family history of premature sudden death/cardiomyopathy, medication review, resting BP and cardiovascular exam. Use a pre-participation screen (e.g. PAR-Q+) and stratify per ACSM/AHA principles.

– Fitness measurement (core):

– Gold standard: cardiopulmonary exercise test (CPET) with directly measured VO₂ max, or a validated maximal/submaximal treadmill or cycle protocol; express result as an age/sex percentile and in METs.[11]

– Wearable-estimated VO₂ max is a useful trend tool but less accurate than CPET — do not use for diagnostic decisions.

– In frailty, prioritise SPPB, gait speed, Timed Up-and-Go, sit-to-stand, grip strength, 6-minute walk over maximal CPET, which is often impractical.[16]

– Baseline investigations (tailored): resting ECG; HbA1c/fasting glucose, lipid profile, U&E, FBC (exclude anaemia limiting VO₂), TFTs, hs-CRP; blood pressure; body composition (DXA if available for sarcopenia/sarcopenic obesity). Consider resting 12-lead ECG and cardiology referral if abnormal screen.[16]

– Risk stratification: classify low/moderate/high risk for exercise-related events using symptoms, known CVD, and risk factor burden; high-risk patients require medical supervision and/or exercise ECG before vigorous intensity.

– Documentation: baseline VO₂ max (percentile + METs), resting HR/HR reserve, BP, body composition, functional battery, and cardiometabolic bloods to allow meaningful serial comparison.

6. Dosing regimens and practical implementation (exercise = the evidence-based “drug”)

– Aerobic base (robust human data):[14][3][8]

– Meet or exceed guideline volume: ≥150 min/week moderate or ≥75 min/week vigorous aerobic activity.

– HIIT (strongest for VO₂ gain): typically 3 sessions/week for 4–16 weeks; walking/running protocols may outperform cycling.[3]

– 4×4 (Norwegian) protocol: 4 × 4-min bouts at ~85–95% HR max, separated by 3-min active recovery at ~60–70% HR max, plus warm-up/cool-down.

– Lower-volume/10-20-30 or 30-s “SIT” formats are time-efficient alternatives.

– MICT (30–60 min continuous at 60–75% HR max) is an effective, lower-risk alternative, especially early or in higher-risk patients.

– Titration: begin with MICT to build an aerobic base, then introduce one HIIT session/week, progressing to 2–3 as tolerated. In frailty, strength and balance training precede aerobic work, and aerobic work starts as short interval walking bouts progressed by frequency/duration before intensity.[16]

– Adjuncts with human support: resistance training ≥2×/week (sarcopenia, function, insulin sensitivity) and protein intake ~1.5 g/kg/day in older adults to potentiate training.[16]

– Dose–response: VO₂ gains are largest from a low baseline and with higher intensity; gains plateau in the already-fit.[3][12]

– Regimens requiring caution / no robust human data: red/near-infrared light therapy, NAD⁺ precursors (NR/NMN), CoQ10, urolithin A, metformin and rapamycin for VO₂ max — mechanistic plausibility only; do not substitute for training.[6][9][4]

7. Monitoring, safety and follow-up

– Monitoring plan: track symptoms (chest pain, undue dyspnoea, dizziness, palpitations), resting BP/HR, adherence, and repeat VO₂ max/functional testing.

– Timepoints: re-assess CRF at 8–12 weeks (expect measurable gain), then every 6–12 months. Repeat cardiometabolic bloods at 3–6 months if being optimised.

– Adverse effects: musculoskeletal injury and overuse are the commonest events with HIIT/high-volume training; ensure warm-up, progression and recovery. Serious cardiac events during exercise are rare in appropriately screened individuals, and the survival benefit of higher-volume aerobic training outweighs the small sudden-death risk in the general population.[14]

– Actions for abnormal findings: stop and refer for exertional chest pain, syncope/near-syncope, new arrhythmia, or a fall in exercise capacity — investigate for occult cardiac disease.

– Interactions: in patients on beta-blockers, HR-based targets are unreliable — use RPE (Borg). Review glucose-lowering therapy (hypoglycaemia risk with increased activity) and antihypertensives.

– Special populations: frailty — function-first, supervised, protein-supplemented; renal/hepatic impairment and extremes of age — individualise and coordinate with existing care; pregnancy/breastfeeding — moderate exercise safe, avoid supraphysiological experimental agents entirely.[16]

8. Contraindications and cautions

– Absolute (to vigorous testing/training until stabilised): acute MI/ACS, unstable angina, decompensated heart failure, symptomatic severe aortic stenosis, uncontrolled symptomatic arrhythmia, acute myocarditis/pericarditis, acute PE/DVT, dissecting aneurysm, acute systemic illness.

– Relative (specialist advice): uncontrolled hypertension, poorly controlled diabetes, moderate valvular disease, hypertrophic cardiomyopathy, advanced frailty, uncontrolled arrhythmia risk — often can train at modified intensity under supervision.

– Harm likely to outweigh benefit: use of off-label pharmacological “mitochondrial/longevity” agents to raise VO₂ max outside a trial — no efficacy evidence and non-trivial adverse-effect and interaction potential.[4][5]

9. Practical management scenarios

Scenario A — Middle-aged adult, multiple cardiometabolic risk factors

– Recommendation: Offer (strong). Highest absolute benefit group.[3][1]

– Assessment: PAR-Q+, resting ECG/BP, cardiometabolic bloods, baseline CPET/estimated VO₂ max percentile.

– Consent: frame training as evidence-based; be explicit that any adjunct supplements are unproven.

– Initiation: 4–6 weeks MICT base → add 1–2 HIIT sessions/week (e.g. 4×4) + resistance training 2×/week.

– Monitoring: re-test VO₂ max and cardiometabolic bloods at 12 weeks; adjust intensity.

– Escalate/stop: exertional cardiac symptoms → cardiology referral.

Scenario B — Older, frail patient with multimorbidity

– Recommendation: Offer a modified, function-first programme (strong for function/QoL; moderate for clinical outcomes).[16][17]

– Assessment: SPPB, gait speed, grip strength, sit-to-stand, 6-minute walk (not maximal CPET); screen cognition, mood, nutrition, sarcopenia.

– Consent/decision: goals framed around independence and fall prevention.

– Initiation: strength + balance first; short interval walking progressed by frequency/duration; protein ~1.5 g/kg/day; supervised where possible.

– Monitoring: serial functional battery and QoL (e.g. EQ-5D) every 8–12 weeks.

– Escalate/refer: falls, unexplained functional decline, or cardiac symptoms.

Scenario C — Patient already under specialist care (adjunct)

– Recommendation: Consider as adjunct, coordinated with the specialist team; do not duplicate or override structured cardiac rehabilitation.[17]

– Assessment: obtain specialist status/clearance; align intensity with existing prescription.

– Initiation/monitoring: integrate with cardiac rehab; use RPE if beta-blocked; share progress with the treating team.

– Stop/refer: any change in underlying disease status → back to specialist.

Across all scenarios, off-label pharmacological agents for VO₂ max/longevity are restricted to research or explicit informed-consent adjuncts, never first-line.[4][5]

10. Research gaps and future directions

– No RCT has tested whether deliberately raising VO₂ max to a defined target reduces hard longevity endpoints; the mortality evidence is observational (though large and consistent).[1][2][18]

– Optimal HIIT prescription (intensity, modality, volume) for VO₂ gain and, separately, for hard outcomes across age strata remains uncertain.[3][12]

– Gerotherapeutics: metformin (TAME), rapamycin, NAD⁺ precursors and senolytics lack human VO₂ max/mortality data; results awaited. These should currently be confined to well-designed trials/registries.[4][5]

– Adjunctive devices/supplements (red-light therapy, urolithin A, CoQ10) need adequately powered human RCTs with VO₂ max as endpoint before clinical use.[6][9]

– Priority questions: does treating low CRF as a vital sign and intervening change outcomes; which frailty-adapted protocols best convert physiological gains into independence; long-term safety of high-volume vigorous training in ageing cohorts.

References

1. Cardiorespiratory Fitness Is a Strong and Consistent Predictor of Morbidity and Mortality Among Adults: An Overview of Meta-Analyses Representing Over 20.9 Million Observations From 199 Unique Cohort Studies. Lang JJ, Prince SA, Merucci K, et al. British Journal of Sports Medicine. 2024;58(10):556-566. doi:10.1136/bjsports-2023-107849.
2. Objectively Assessed Cardiorespiratory Fitness and All-Cause Mortality Risk: An Updated Meta-Analysis of 37 Cohort Studies Involving 2,258,029 Participants. Laukkanen JA, Isiozor NM, Kunutsor SK. Mayo Clinic Proceedings. 2022;97(6):1054-1073. doi:10.1016/j.mayocp.2022.02.029.
3. High-Intensity Interval Training and Cardiometabolic Health in the General Population: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Edwards JJ, Griffiths M, Deenmamode AHP, O’Driscoll JM. Sports Medicine (Auckland, N.Z.). 2023;53(9):1753-1763. doi:10.1007/s40279-023-01863-8.
4. Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. Espinoza SE, Khosla S, Baur JA, de Cabo R, Musi N. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(Suppl 1):53-60. doi:10.1093/gerona/glad034.
5. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
6. Enhancing Healthy Aging With Small Molecules: A mitochondrial Perspective. Qin X, Li H, Zhao H, Fang L, Wang X. Medicinal Research Reviews. 2024;44(4):1904-1922. doi:10.1002/med.22034.
7. Mitochondrial dysfunction in cell senescence and aging. Miwa S, Kashyap S, Chini E, von Zglinicki T. The Journal of Clinical Investigation. 2022;132(13):e158447. doi:10.1172/JCI158447.
8. High-Intensity Interval Training for Reducing Cardiometabolic Syndrome in Healthy but Sedentary Populations. Strauss JA, Kirwan R, Ranasinghe C, et al. The Cochrane Database of Systematic Reviews. 2026;3:CD013617. doi:10.1002/14651858.CD013617.pub2.
9. The Potential of Mitochondrial Therapeutics in the Treatment of Oxidative Stress and Inflammation in Aging. Sinha JK, Jorwal K, Singh KK, et al. Molecular Neurobiology. 2025;62(6):6748-6763. doi:10.1007/s12035-024-04474-0.
10. Ageing and rejuvenation of tissue stem cells and their niches. Brunet A, Goodell MA, Rando TA. Nature Reviews. Molecular Cell Biology. 2023;24(1):45-62. doi:10.1038/s41580-022-00510-w.
11. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Ross R, Blair SN, Arena R, et al. Circulation. 2016;134(24):e653-e699. doi:10.1161/CIR.0000000000000461.
12. One Size Does Not Fit All: A Meta‐Analysis of 115 Trials Comparing High‐Intensity Interval and Moderate‐to‐Vigorous‐Intensity Continuous Training Across Diverse Participants, Protocols, and Outcomes. Bi Z, Yin M, Xu K, et al. Scandinavian Journal of Medicine & Science in Sports. 2026;36(3):e70243. doi:10.1111/sms.70243.
13. High‐intensity interval training and cardiorespiratory fitness in adults: An umbrella review of systematic reviews and meta‐analyses. Poon ET, Li HY, Gibala MJ, Wong SH, Ho RS. Scandinavian Journal of Medicine & Science in Sports. 2024;34(5):e14652. doi:10.1111/sms.14652.
14. Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4. Tucker WJ, Fegers-Wustrow I, Halle M, et al. Journal of the American College of Cardiology. 2022;80(11):1091-1106. doi:10.1016/j.jacc.2022.07.004.
15. Cardiorespiratory Fitness and Mortality Risk Across the Spectra of Age, Race, And Sex. Kokkinos P, Faselis C, Samuel IBH, et al. Journal of the American College of Cardiology. 2022;80(6):598-609. doi:10.1016/j.jacc.2022.05.031.
16. Exercise Training in High-Risk Populations: A Scientific Statement From the American Heart Association. Fleg JL, Golbus JR, Afilalo J, et al. Circulation. 2026;154(8):e319-e338. doi:10.1161/CIR.0000000000001456.
17. Cognitive Impairment and Frailty in Older Adults With Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. Alexander KP, Damluji AA, Erqou S, et al. Journal of the American College of Cardiology. 2026;:S0735-1097(26)07126-3. doi:10.1016/j.jacc.2026.07.009.
18. Cardiorespiratory Fitness and Mortality From All Causes, Cardiovascular Disease and Cancer: Dose-Response Meta-Analysis of Cohort Studies. Han M, Qie R, Shi X, et al. British Journal of Sports Medicine. 2022;56(13):733-739. doi:10.1136/bjsports-2021-104876.